Minimum age of 11 set for UK puberty blocker trial
A clinical trial for puberty-blocking drugs in the UK has set a minimum age of 11 for participants following safety concerns raised by regulators. The trial, which has faced legal scrutiny, will include strict safeguards and parental consent requirements.
Why it matters
This trial is a focal point in the ongoing debate regarding gender-affirming care for minors and the ethical standards for medical research involving children.
Share Save Add as preferred on Google Alison Holt Social affairs correspondent Getty Images Gender-questioning children will have to be at least 11 years old to take part in a clinical trial assessing the risks and benefits of puberty-blocking drugs.
The article presents the trial's constraints and the context of the controversy without taking a side on the medical or ethical debate.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in